pah-protein

pah-protein

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">pah-protein</th>
</tr>
<tr>
<td class="label">Regulatory Mechanism</td>
<td>Effect on PAH Activity</td>
</tr>
<tr>
<td class="label">Phenylalanine concentration</td>
<td>Allosteric activation at high [Phe]</td>
</tr>
<tr>
<td class="label">Phosphorylation (Ser16)</td>
<td>Increases specific activity</td>
</tr>
<tr>
<td class="label">BH₄ availability</td>
<td>Absolute requirement for catalysis</td>
</tr>
<tr>
<td class="label">Hepatic phenylalanine levels</td>
<td>Diurnal variation in activity</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">151 edges</a></td>
</tr>
</table>

pah-protein

Introduction

<table class="infobox infobox-protein">
<tr>
<th class="infobox-header" colspan="2">pah-protein</th>
</tr>
<tr>
<td class="label">Regulatory Mechanism</td>
<td>Effect on PAH Activity</td>
</tr>
<tr>
<td class="label">Phenylalanine concentration</td>
<td>Allosteric activation at high [Phe]</td>
</tr>
<tr>
<td class="label">Phosphorylation (Ser16)</td>
<td>Increases specific activity</td>
</tr>
<tr>
<td class="label">BH₄ availability</td>
<td>Absolute requirement for catalysis</td>
</tr>
<tr>
<td class="label">Hepatic phenylalanine levels</td>
<td>Diurnal variation in activity</td>
</tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a>, <a href="/wiki/alzheimer" style="color:#ef9a9a">Alzheimer</a>, <a href="/wiki/amyotrophic-lateral-sclerosis" style="color:#ef9a9a">Amyotrophic Lateral Sclerosis</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">151 edges</a></td>
</tr>
</table>

Phenylalanine Hydroxylase (PAH) is a crucial enzyme in phenylalanine metabolism, catalyzing the rate-limiting step in the catabolic pathway that converts the essential amino acid L-phenylalanine to L-tyrosine [blau2010](https://pubmed.ncbi.nlm.nih.gov/21040663/). This iron-dependent, tetrahydrobiopterin (BH₄)-requiring enzyme is essential for maintaining phenylalanine homeostasis, and its dysfunction leads to phenylketonuria (PKU), the most common inherited metabolic disorder of amino acid metabolism.

PAH is expressed primarily in the liver, where it functions as a homotetramer to metabolize the majority of dietary phenylalanine. However, PAH is also expressed at lower levels in the kidney and brain, where its activity is critical for local tyrosine synthesis and neurotransmitter production [scriver2008](https://pubmed.ncbi.nlm.nih.gov/19051295/). The brain-specific isoform plays important roles in neuronal function, influencing the synthesis of dopamine, norepinephrine, and melanin precursors.

Beyond its well-established role in PKU, emerging research has revealed connections between altered phenylalanine metabolism and neurodegenerative diseases including Alzheimer's disease (AD) and Parkinson's disease (PD). Elevated phenylalanine levels and altered PAH activity have been documented in these conditions, suggesting potential roles in disease pathogenesis and offering novel biomarker possibilities [cacciola2016](https://pubmed.ncbi.nlm.nih.gov/26476835/).

This page provides a comprehensive overview of PAH's molecular structure, catalytic mechanism, physiological functions, and implications in both metabolic and neurodegenerative disorders.

Structure

Domain Architecture

PAH is a homotetrameric enzyme with each subunit consisting of approximately 507 amino acids and a molecular weight of ~52 kDa. The protein is organized into three distinct functional domains:

Crystal Structure

The crystal structure of human PAH has been solved in multiple conformational states (PDB: 1PHZ, 2PAH, 1J8U), revealing:

• The detailed architecture of the catalytic center
• The BH₄ binding pocket and its interactions with the cofactor
• The conformational changes accompanying substrate binding
• The oligomerization interface at the C-terminus [vargas2019](https://pubmed.ncbi.nlm.nih.gov/31795380/)

Cofactor Requirements

PAH requires multiple cofactors for catalytic activity:

• Ferrous Iron (Fe²⁺): The catalytic center contains a tightly bound iron ion that participates directly in the hydroxylation reaction
• Tetrahydrobiopterin (BH₄): The essential cofactor that serves as both a reducing agent and participant in the catalytic cycle
• Molecular Oxygen (O₂): Required as the oxidant for the hydroxylation reaction

Normal Function

Catalytic Mechanism

PAH catalyzes the conversion of L-phenylalanine to L-tyrosine through a complex oxidative reaction:

Overall Reaction:
L-Phenylalanine + O₂ + BH₄ → L-Tyrosine + H₂O + BH₂ (dihydrobiopterin)

The catalytic mechanism proceeds through several steps:

Regulation

PAH activity is tightly regulated through multiple mechanisms:

Physiological Role

In the liver, PAH functions as part of the phenylalanine catabolic pathway that prevents accumulation of this potentially neurotoxic amino acid. The tyrosine produced serves as:

• Precursor for catecholamine neurotransmitters (dopamine, norepinephrine)
• Substrate for melanin synthesis
• Component in protein synthesis
• Precursor for thyroid hormone (T₃, T₄)

Role in Disease

Phenylketonuria (PKU)

PAH deficiency is the genetic cause of phenylketonuria, an autosomal recessive disorder affecting approximately 1 in 10,000-15,000 births worldwide [blau2010](https://pubmed.ncbi.nlm.nih.gov/21040663/).

Genetics: Over 600 pathogenic variants have been identified in the PAH gene, including:

• Missense mutations (most common, ~60%)
• Nonsense mutations (~15%)
• Splice-site mutations (~15%)
• Small deletions/insertions (~10%)

• Accumulation of phenylalanine in blood and tissues
• Deficiency of tyrosine and downstream metabolites
• Direct neurotoxicity of elevated phenylalanine
• Impaired transport of other amino acids across the blood-brain barrier

• Intellectual disability (if untreated)
• Microcephaly
• Seizures
• Eczema
• Musty odor
• Hypopigmentation

• Lifelong phenylalanine-restricted diet [matalon2004](https://pubmed.ncbi.nlm.nih.gov/15507178/)
• Sapropterin dihydrochloride (BH₄) supplementation for responsive patients [levy2007](https://pubmed.ncbi.nlm.nih.gov/17236790/)
• Pegvaliase (PEGylated phenylalanine ammonia lyase) for adults
• Gene therapy under clinical investigation

Alzheimer's Disease

Altered phenylalanine metabolism has been documented in Alzheimer's disease:

Findings:

• Elevated plasma phenylalanine levels in AD patients compared to controls [cacciola2016](https://pubmed.ncbi.nlm.nih.gov/26476835/)
• Reduced tyrosine availability affecting catecholamine synthesis
• Altered BH₄ metabolism impacting neuronal function
• Association between elevated phenylalanine and disease severity

• Phenylalanine-induced oxidative stress in neurons
• Impaired neurotransmitter synthesis contributing to cognitive decline
• Dysregulation of one-carbon metabolism
• Competition with other large neutral amino acids for transport

Parkinson's Disease

Findings:

• Altered phenylalanine metabolism in PD patients
• Elevated phenylalanine:tyrosine ratio as potential biomarker
• Impaired BH₄ synthesis affecting dopaminergic neurons
• Interaction with levodopa treatment response

• Phenylalanine tolerance may vary in PD
• Nutritional interventions targeting amino acid balance
• Monitoring phenylalanine in patients undergoing dopaminergic therapy

Other Conditions

• Tyrosinemia: Secondary to severe PAH deficiency
• Hyperphenylalaninemia: Broader category including BH₄ deficiencies
• Maternal PKU: Teratogenic effects on fetus during pregnancy

Therapeutic Implications

Pharmacological Approaches

Sapropterin Dihydrochloride (BH₄):

• Synthetic cofactor that can stabilize mutant PAH enzymes
• Effective in approximately 30-50% of PKU patients
• Requires loading dose followed by maintenance therapy [levy2007](https://pubmed.ncbi.nlm.nih.gov/17236790/)

• PEGylated phenylalanine ammonia lyase
• Converts phenylalanine to trans-cinnamic acid and ammonia
• Administered via subcutaneous injection
• Approved for adults with PKU

• Small molecules that stabilize mutant PAH protein
• Increase residual enzyme activity
• Under clinical investigation

Gene Therapy

AAV-mediated PAH gene delivery has shown promise in preclinical models:

• Correction of metabolic abnormalities in PAH-deficient mice
• Sustained expression of functional enzyme
• Potential for single-dose treatment
• Clinical trials ongoing

Dietary Management

The cornerstone of PKU treatment remains dietary phenylalanine restriction:

• Natural protein restriction
• Phe-free amino acid supplements
• Special low-protein medical foods
• Monitoring of blood Phe levels [longo2004](https://pubmed.ncbi.nlm.nih.gov/15557116/)

Summary

Phenylalanine Hydroxylase (PAH) is an essential enzyme in phenylalanine catabolism, catalyzing the conversion of phenylalanine to tyrosine. Loss-of-function mutations in PAH cause phenylketonuria (PKU), the most common inborn error of metabolism, characterized by neurotoxic phenylalanine accumulation and, without treatment, severe neurological damage. The enzyme requires ferrous iron and tetrahydrobiopterin (BH₄) as cofactors, and its activity is regulated by substrate concentration and post-translational modifications.

Beyond its central role in PKU, emerging evidence links altered phenylalanine metabolism to neurodegenerative diseases. Elevated phenylalanine levels have been documented in Alzheimer's disease and Parkinson's disease, where they may contribute to disease pathogenesis through oxidative stress, impaired neurotransmitter synthesis, and metabolic dysregulation. Understanding PAH function and its connections to neurodegeneration offers insights into disease mechanisms and potential therapeutic approaches.

See Also

• [PAH Gene](/genes/pah) — Gene encoding phenylalanine hydroxylase
• [Phenylketonuria](/diseases/phenylketonuria) — Inherited metabolic disorder from PAH deficiency
• [Tetrahydrobiopterin](/proteins/bh4-protein) — Essential cofactor for PAH
• [Tyrosine](/proteins/tyrosine) — Product of PAH-catalyzed reaction
• [Alzheimer's Disease](/diseases/alzheimers-disease) — Neurodegenerative disease with altered amino acid metabolism
• [Parkinson's Disease](/diseases/parkinsons-disease) — Neurodegenerative disease with altered phenylalanine metabolism
• [Dopamine Synthesis](/pathways/dopamine-biosynthesis) — Pathway utilizing tyrosine from PAH

References